These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12032218)

  • 1. Sirolimus tolerability in a kidney transplant recipient with acute intermittent porphyria.
    El-Haggan W; Lobbedez T; Ryckelynck JP; Hurault de Ligny B
    Nephrol Dial Transplant; 2002 Jun; 17(6):1147. PubMed ID: 12032218
    [No Abstract]   [Full Text] [Related]  

  • 2. The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria.
    Barone GW; Gurley BJ; Anderson KE; Ketel BL; Abul-Ezz SR
    J Clin Pharmacol; 2001 Jan; 41(1):113-5. PubMed ID: 11144989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary alveolar proteinosis in a kidney transplant: a rare complication of sirolimus.
    Kadikoy H; Paolini M; Achkar K; Suki W; Gaber AO; Anwar N; Jeroudi A; Barrios R; Abdellatif A
    Nephrol Dial Transplant; 2010 Aug; 25(8):2795-8. PubMed ID: 20484303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus use and de novo minimal change nephropathy following renal transplantation.
    Mainra R; Mulay A; Bell R; Karpinski J; Hoar S; Knoll G; Robertson S; Wang D
    Transplantation; 2005 Dec; 80(12):1816. PubMed ID: 16378080
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy.
    Edwards C; House A; Shahinian V; Knoll G
    Nephrol Dial Transplant; 2002 Aug; 17(8):1524-6. PubMed ID: 12147807
    [No Abstract]   [Full Text] [Related]  

  • 6. Pretransplant evaluation of a patient with acute intermittent porphyria.
    Turton-Weeks S; Barone GW; Gurley BJ; Ketel BL; Lightfoot ML; Abul-Ezz SR; Anderson KE
    Prog Transplant; 2001 Sep; 11(3):214-6. PubMed ID: 11949465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity.
    Chang HR; Lee MH; Wen MC; Lian JD
    Transplant Proc; 2004 Nov; 36(9):2668-70. PubMed ID: 15621119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is sirolimus a nephrotoxic drug? A report of five cases.
    Sabry AA; Elagroudy AE; El-dahshan KF; El-Rahim MA; Sobh MA
    Transplant Proc; 2007 Jun; 39(5):1406-9. PubMed ID: 17580149
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe sirolimus-induced acute hepatitis in a renal transplant recipient.
    Jacques J; Dickson Z; Carrier P; Essig M; Guillaudeau A; Lacour C; Bocquentin F; Aldigier JC; Rerolle JP
    Transpl Int; 2010 Sep; 23(9):967-70. PubMed ID: 20497403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient.
    Alfano G; Fontana F; Mori G; Vicari E; Dolci G; Franceschini E; Guaraldi G; Mussini C; Cappelli G
    Int J STD AIDS; 2019 Aug; 30(9):919-922. PubMed ID: 31280689
    [No Abstract]   [Full Text] [Related]  

  • 11. Sirolimus after kidney transplantation.
    Sharif A
    BMJ; 2014 Nov; 349():g6808. PubMed ID: 25424845
    [No Abstract]   [Full Text] [Related]  

  • 12. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of encapsulating peritoneal sclerosis in a renal transplant recipient on sirolimus immunotherapy.
    Temple S; Zaltzman J; Perl J
    Perit Dial Int; 2010; 30(4):475-7. PubMed ID: 20628110
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of sirolimus for Epstein-Barr virus-positive smooth-muscle tumour.
    Toh HC; Teo M; Ong KW; Lee V; Chan E; Lee AS; Vathsala A
    Lancet Oncol; 2006 Nov; 7(11):955-7. PubMed ID: 17081922
    [No Abstract]   [Full Text] [Related]  

  • 15. Giant warts in a kidney transplant patient: regression with sirolimus.
    Kostaki M; Venetz JP; Nseir G; Meylan P; Sahli R; Pascual M; Laffitte E
    Br J Dermatol; 2010 May; 162(5):1148-50. PubMed ID: 20346038
    [No Abstract]   [Full Text] [Related]  

  • 16. Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up.
    Nafar M; Alipour B; Ahmadpoor P; Pour-Reza-Gholi F; Samadian F; Samavat S; Farhangi S
    Iran J Kidney Dis; 2012 Jul; 6(4):300-6. PubMed ID: 22797101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-induced intractable chronic diarrhea: a case report.
    Alkhatib AA
    Transplant Proc; 2006 Jun; 38(5):1298-300. PubMed ID: 16797287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients.
    Flechner SM; Zhou L; Derweesh I; Mastroianni B; Savas K; Goldfarb D; Modlin CS; Krishnamurthi V; Novick A
    Transplantation; 2003 Dec; 76(12):1729-34. PubMed ID: 14688524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.
    Mathis AS; Shah NK; Friedman GS
    Transplant Proc; 2004 Nov; 36(9):2708-9. PubMed ID: 15621130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.
    Mohsin N; Budruddin M; Pakkyara A; Darweesh A; Nayyer M; Amitabh J; Daar AS
    Exp Clin Transplant; 2005 Dec; 3(2):366-9. PubMed ID: 16417445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.